Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

What's New

Last Updated: February 8, 2019; Last Reviewed: February 8, 2019

After the 2013 full guidelines release, the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children (the Panel) modified its process so that individual sections would be published as they were updated, allowing for more timely appearance of new recommendations. Each section will be marked with the date of its last update and the summary of changes will be listed below. For a full description of the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children, see the updated Summary.

Additionally, the evidence review and recommendation rating system underwent major changes; this new approach is incorporated into sections as they are individually updated. As a result, topics not yet updated since the 2013 release reflect the former rating system, and sections updated since 2013 use a newer, modified GRADE system. A description of the methods of collecting and synthesizing evidence and formulating and rating recommendations appears in the Background and Recommendations Rating Scheme section. 

Major section revisions within the last 6 months are as follows:

February 8, 2019

  1. Isosporiasis (Cystoisosporiasis): There are no major changes to the guidance for the diagnosis and management of Isosporiasis (Cystoisosporiasis) in children and adolescents living with HIV. The section has been updated to reflect the new recommendation rating system and references were added.

January 31, 2019

  1. Candida Infections: There are no major changes to the guidance for the diagnosis and management of Candida Infections in children and adolescents living with HIV. Minor updates to the main text of the section include new diagnostic methodologies and a restructured subsection on Pharmacokinetics and Dosing of Antifungals, including the newer agents posaconazole and isavuconazole. The section has been updated to reflect the new recommendation rating system and references were added.

January 8, 2019

  1. Mycobacterium avium Complex Disease: There are no major changes to the guidance for the diagnosis and management of Mycobacterium avium Complex Disease in children and adolescents living with HIV. The section has been updated to reflect the new recommendation rating system and references were added.

Download Guidelines